Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 11/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 9/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL28016400 | 0.86 | ALOX15 (0.39) | KDM4EMEN1KMT2ACYP1A2ALOX15 | |
| SCHEMBL65380 | 0.86 | PDE3B (0.42) | KMT2AALOX15PDE3BPDE3ACYP2C19 | |
| Fluoride SCHEMBL1666139 | 0.84 | PDE3B (0.41) | ALOX15PDE3BPDE3A | |
| SCHEMBL844233 | 0.77 | PDE3B (0.39) | KDM4EALDH1A1KMT2ARECQLALOX15 | |
| SCHEMBL15527710 | 0.74 | GABRP (0.46) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL16414244 | 0.73 | NOS2 (0.41) | CYP1A2PDE3BPDE3ACYP3A4CYP2C19 | |
| SCHEMBL25652166 | 0.73 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL13066841 | 0.73 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL844120 | 0.73 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL7064794 | 0.72 | NOS2 (0.42) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927028-B2 | Pharmaceutical composition containing coated, floating particles | JAGOTEC AG (CH) | 2015-01-06 | — | — | US | claimed |
| US-20080317841-A1 | Pharmaceutical Composition Containing Coated, Floating Particles | JAGOTEC AG (CH) | 2008-12-25 | — | — | US | claimed |
| EP-1835893-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | Jagotec AG (CH) | 2007-09-26 | — | — | EP | claimed |
| WO-2006063858-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COATED, FLOATING PARTICLES | JAGOTEC AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240148990-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240148646-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4351517-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven Biopharma Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240100272-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11872308-B2 | Dry powder formulations of epinephrine and associated methods | Belhaven BioPharma Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230240983-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230233460-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-07-27 | — | — | US | disclosed |
| US-6120803-A | Prolonged release active agent dosage form adapted for gastric retention | ALZA CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| WO-2000038650-A1 | GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS | ALZA CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038655-A1 | DOSAGE FORMS COMPRISING POROUS PARTICLES | ALZA CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-1003476-A1 | PROLONGED RELEASE ACTIVE AGENT DOSAGE FORM ADAPTED FOR GASTRIC RETENTION | ALZA CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000025753-A2 | CONTROLLED DELIVERY OF ACTIVE AGENTS | ALZA CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999007342-A1 | PROLONGED RELEASE ACTIVE AGENT DOSAGE FORM ADAPTED FOR GASTRIC RETENTION | ALZA CORPORATION (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1995007672-A1 | RECTALLY-ADMINISTERED, EPILEPTIC-SEIZURE-INHIBITING COMPOSITION | ATHENA NEUROSCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |